Use of cannabidiol in the treatment of epilepsy.
Level 5 - mechanism / opinion, no new human data
Narrative position paper reviewing existing clinical trial evidence and mechanisms without systematic search or meta-analysis.
PubMed 35211946 · doi:10.5603/PJNNS.a2022.0020
What was done
This position paper reviewed the anti-seizure mechanisms of action, current clinical indications, and trial outcomes of cannabidiol (specifically the approved drug Epidiolex) for treating drug-resistant epilepsy.
What was found
The abstract reports no numerical data or effect sizes. It notes that completed randomized, placebo-controlled clinical trials demonstrated that cannabidiol reduces seizures in drug-resistant epilepsy, particularly in Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex.
Why it matters
It outlines the clinical rationale and regulatory indications for the only FDA- and EMA-approved cannabis-derived formulation for severe pediatric epilepsy syndromes.
Limits
This is a narrative position paper rather than a systematic review or meta-analysis. The abstract reports no quantitative findings, sample sizes, adverse effect profiles, or specific trial evaluation criteria.
Cited by
- supports Cannabidiol (CBD) has received regulatory approval for the treatment of pediatric epilepsy syndromes, specifically Lennox-Gastaut syndrome and Dravet syndrome.